ArticleTherapeutic advances in hematology2012
Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.
Article in Therapeutic advances in hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.Virchows Archiv : an international journal of pathology · 2022Pooled it
- Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.Cancer communications (London, England) · 2019Trial
- Article
- Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment.The Journal of investigative dermatology · 2023Review
- Primary pituitary stalk mucosa-associated lymphoid tissue lymphoma: a case report and literature review.Frontiers in neurology · 2023Article
- IgG4-associated hypophysitis coexisting with MALT lymphoma and gangliocytoma: first case report and literature review.Frontiers in neurology · 2023Article
- Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience.Medicina (Kaunas, Lithuania) · 2019Observational
- LSD1 Cooperates with Noncanonical NF-κB Signaling to Regulate Marginal Zone B Cell Development.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Effective management strategies for patients with marginal zone lymphoma.Future oncology (London, England) · 2018Review
- Surgical management of splenic marginal zone lymphoma.Irish journal of medical science · 2018Article
- Psychological distress, chronic conditions and quality of life in elderly hematologic cancer patients: study protocol of a prospective study.BMC cancer · 2017Article
- Primary B-Cell Mucosa-Associated Lymphoid Tissue Lymphoma of the Hard Palate and Parotid Gland: Report of One Case and Review of the Literature.Journal of clinical medicine research · 2016Article
- MALT lymphoma of the left biceps muscle: a rare case with an interesting presentation.SpringerPlus · 2016Article
- Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.International journal of hematology · 2016Article
- [Clinical characteristics and prognostic analysis of 90 patients with primary gastro-intestinal marginal zone lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Clinical aspects of malt lymphomas.Current hematologic malignancy reports · 2014Review
- Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma.World journal of oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marginal zone lymphoma (MZL) is an indolent B-cell lymphoma arising from marginal zone B-cells present in lymph nodes and extranodal tissues. MZL comprises 5-17% of all non-Hodgkin's lymphomas in adults. The World Health Organization categorizes MZL into three distinct types based on their site of impact: (1) splenic marginal zone lymphoma (SMZL); (2) nodal marginal zone lymphoma (NMZL); (3) extranodal mucosa-associated lymphoid tissue (MALT) lymphoma, which can be subdivided into gastric and nongastric. The subgroups of MZL share some common features but are different in their biology and behavior. Owing to the rarity of MZL there are few randomized trials available comparing various treatment options and therefore treatment is controversial, lacking standard guidelines. Treatment should be patient tailored and can range from a 'watchful waiting' approach for asymptomatic patients without cytopenias to surgery or localized radiation therapy. Rituximab in combination with chemotherapy has resulted in longer failure-free survival than chemotherapy alone in patients with SMZL. Helicobacter pylori positive gastric MALT shows a good response rate to triple antibiotic therapy. Newer therapies such as bendamustine, everolimus, lenalidomide, vorinostat and phosphoinositide 3-kinase inhibitors are in clinical trials for patients with relapsed or refractory MZL and have shown promising results. We are presently conducting clinical trials testing the efficacy of the epigenetic activity of cladribine as a hypomethylating agent in combination with the histone deacetylase inhibitor (HDACi) vorinostat and rituximab in patients with MZL. Further studies with the newer agents should be done both in newly diagnosed or relapsed/refractory MZL to streamline the care and to avoid the use of toxic chemotherapies as initial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.